MNCLU Expected to Price Tonight for Trading Tomorrow
Monocle Acquisition Corporation (MNCLU), revised terms and re-filed their S-1 this morning. Notably, the amount held in trust increased to 101% or $10.10 per share. As such, the amount of at-risk capital was increased as well from $5 million to $6.5 million (650K units at $10.00).
Additionally, Monocle will still be contributing $0.10 per share to the trust if they need to use a three-month extension to complete their combination, on top of their stated 21 months. That means the trust could potentially reach 102% or $10.20 per share if they need to use the full 24 months. No other terms were amended.
These terms now look to be more appropriate and are certainly attractive enough to get the deal done. Pricing is still anticipated to occur tonight, February 6th, for trading tomorrow.
A revised summary of terms has been provided below:
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...